What Skican Treats: Main Uses and Benefits

Skican (Fluconazole) is generally used to help manage fungal infections across various body systems. The medication is relevant for addressing conditions such as Candidemia (fungal bloodstream infection), Cryptococcal Meningitis (fungal brain infection), and localized infections like oropharyngeal or vaginal candidiasis.

Symptom Relief and Therapeutic Scope

In acute settings, Skican is commonly used for supportive management of the underlying fungal pathology of deep-seated infections, which may assist with maintaining functional stability during periods of heightened systemic burden. For mucosal infections, the medicine helps ease symptom clusters that may become intense or disruptive, including burning, severe itching, and painful swallowing.

The medication also plays a role in managing symptoms associated with recurrent or episodic manifestations. It is applied in high-risk patient groups, such as those with compromised immune systems, to provide additional symptomatic support for managing risk related to the onset or relapse of severe systemic fungal disease.

“This medication provides support that helps ease the overall symptom burden in situations where symptoms interfere with routine activities.”

---

Quick Fact: Therapeutic Area: Localized Symptom Management The medicine is commonly used across conditions presenting with localized discomfort or inflammatory states, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Regulatory References

1. NIH MedlinePlus overview

Eligibility for Skican (Fluconazole)

Official regulatory information defines specific populations that are permitted, restricted, or prohibited from using Skican.

Classification	Population	Status
Absolute Contraindication	Known hypersensitivity to fluconazole or azole derivatives	Must not use
	Patients taking Cisapride, Pimozide, Quetiapine, or Erythromycin	Must not use
	Patients taking Terfenadine at doses of 400 mg or greater	Must not use
Age Groups	Adults and Adolescents (12-17 years)	Established use
	Pediatric patients (including neonates)	Established for specific indications
	Safety for genital candidiasis in children	Not established
Physiological/Comorbid Status	Chronic or high-dose use in Pregnancy	Generally contraindicated or not recommended
	Patients with Renal Impairment (CrCl leq 50 ml/min)	Conditional use (requires dose reduction)
	Patients with Hepatic Impairment	Conditional use (requires caution/monitoring)

Eligibility is defined by specific label constraints. The medicine is contraindicated when specific drug combinations are present due to the risk of serious cardiac events. Use is restricted in patients with impaired liver or kidney function, and chronic high-dose use is generally prohibited during pregnancy.

Interactions with other medicines and products

Skican (fluconazole) has a defined profile of interactions with other drugs that is primarily mediated through its effect on specific liver enzymes. Fluconazole is an inhibitor of the cytochrome P450 (CYP) enzyme system, specifically CYP2C9 and CYP3A4, which are responsible for the metabolism of many medicines. By inhibiting these enzymes, Skican can increase the concentration of other drugs in the body, which raises the risk of adverse effects.

Clinically Significant Drug Interactions

Co-administration of Skican is contraindicated with certain medications due to the potential for serious or life-threatening cardiac events, including terfenadine and cisapride. Use with astemizole is generally cautioned for the same reason.

Caution is warranted when Skican is used with medicines that have a narrow therapeutic window, as the resulting increased drug levels can lead to toxicity. Medicines whose clearance may be significantly inhibited by Skican include:

• Anticoagulants (e.g., warfarin): Increased bleeding risk.
• Anticonvulsants (e.g., phenytoin).
• Immunosuppressants (e.g., cyclosporine, tacrolimus): Increased risk of nephrotoxicity with tacrolimus.
• Sulfonylureas (e.g., glipizide, tolbutamide).
• Theophylline (a bronchodilator).

Separately, other drugs can affect Skican itself. For instance, co-administration with hydrochlorothiazide may decrease Skican’s clearance. Rifampicin can significantly decrease Skican's plasma concentration by inducing its metabolism.

Other Interactions

Skican can also interact with certain oral contraceptives containing ethinyl estradiol, potentially altering the level of the hormones. Consult a healthcare professional regarding all other prescription, over-the-counter medicines, vitamins, and herbal products to prevent potentially significant drug-drug interactions. Its use is generally cautioned in patients with renal or hepatic impairment due to altered drug clearance.

Selective Enzyme Inhibition and Fungal Cell Arrest

Skican's mechanism is driven by its action as a highly selective competitive inhibitor of the fungal enzyme 14alpha-demethylase ( CYP51). This enzyme is crucial for the ergosterol biosynthesis pathway of the fungus. By blocking the conversion of lanosterol to ergosterol, the drug disrupts the structural and functional integrity of the fungal cell membrane. The primary physiological result is the cessation of fungal growth and reproduction.

Structural Failure Through Cascade Disruption

The inhibition triggers a dual mechanistic cascade: it causes the depletion of essential ergosterol and promotes the accumulation of toxic 14alpha-methyl sterols. These two effects lead to the fungal cell membrane becoming leaky and structurally unsound. This severe functional failure prevents the organism from reproducing, which reduces the fungal population.

Constraints on Mechanistic Efficacy

The mechanism is subject to limitations, primarily fungal resistance mechanisms. The most common constraint involves the fungus overexpressing efflux pump proteins (e.g., CDR and MDR transporters) that actively pump the drug out of the cell, reducing the concentration available to inhibit CYP51. Reduced drug-target affinity due to ERG11 gene mutations also limits the mechanism's effectiveness in certain biological contexts.

Official Administration Guidelines

Skican (Fluconazole) is administered through two primary, officially approved routes: orally or by intravenous infusion. The selection depends on the patient's condition and ability to take oral forms, as the medicine's nearly complete oral absorption allows for the same daily dose to be used when switching between the two routes.

---

Administration Scope

Entity	Official Label Data
Route of administration	The medicine is administered either orally (tablet, capsule, or suspension) or by intravenous infusion.
Dosing schedule	Treatment begins with a loading dose on the first day, typically double the maintenance dose, followed by a once daily regimen. Maintenance doses generally range from 50 mg to 400 mg.
Timing in relation to meals	Oral forms may be taken with or without food, as absorption is not clinically affected.
Preparation requirements	The oral suspension must be shaken well before accurate measurement. Intravenous infusion must be administered slowly, at a rate not exceeding 10 mL/minute.
Age-group administration rules	Pediatric dosing is calculated based on body weight. Neonates require specific extended dosing intervals. Older adults without renal impairment receive the standard adult dosage.
Special procedural conditions	A mandatory dose reduction must be implemented for patients with documented renal impairment (creatinine clearance le 50 mL/min) after the initial loading dose.

---

Course Duration Principle

Treatment duration ranges from a single, acute dose (e.g., 150 mg) to long-term continuation for several months or indefinitely for relapse prevention. The length of therapy for non-single dose regimens is determined by the required clinical and mycological response.

Research Evidence / Overview of Studies for Skican

---

Evidence for Managing Mucosal Fungal Infections

Research into Skican's use for localized fungal infections, such as oral thrush (Oropharyngeal/Esophageal Candidiasis) and vaginal yeast infections (Vulvovaginal Candidiasis), has primarily been conducted through short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring measurements of how symptoms changed over time and how fungal presence was tracked. Outcomes related to physical discomfort—like burning or pain—were monitored, along with measurements of fungal clearance. Specific studies were conducted in standard adult populations and in individuals with certain conditions, such as those with compromised immune function. Studies report patterns related to fungal clearance measurements observed shortly after the study period, with the frequency of symptoms returning being tracked following the completion of the short-term treatment phase.

---

Evidence for Treating Systemic and Deep-Seated Infections

Skican was studied for managing more severe, systemic fungal pathology, including fungal infections in the bloodstream (Candidemia) and the central nervous system (Cryptococcal Meningitis). The evidence base is built upon RCTs and large-scale observational cohort studies, particularly in critically ill patients and individuals with severely compromised immune systems. For these serious conditions, studies monitored outcomes related to overall survival rates and measurements of fungal presence in the bloodstream or spinal fluid. Research describes that findings were mixed regarding specific fungal species, and evidence remains limited regarding studies of Skican alone during the most acute phase of these infections.

---

What Research Gaps and Uncertainties Remain

The research evidence highlights what is known—and what is still uncertain. Evidence quality varies across studies, particularly when comparing older trials with newer, large-scale RCTs. Research so far indicates that comparative evidence is lacking in some areas, such as head-to-head performance against all available newer antifungals. The results apply only to the populations studied, meaning the applicability of findings to patients with rare comorbidities or non-standard fungal species may be uncertain. Furthermore, the selection of fungal resistance, where a fungus becomes less susceptible to treatment, is an area of complex evaluation for which research is ongoing.

Key Studies & References

1. Cryptococcosis: Adult and Adolescent Opportunistic Infections - NIH Clinical Info Guideline
2. Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis
3. WHO Model List of Essential Medicines

Common questions about Skican (FAQ)

Q: Does this medicine make you drowsy or affect your ability to drive?

A: Yes, official product information indicates that drowsiness, fatigue, and somnolence (sleepiness) are reported side effects. Patients taking this product are cautioned against engaging in activities that require complete mental alertness, such as driving a car or operating heavy machinery.

Q: Can I drink alcohol while taking this medication?

A: Regulatory documents advise that concurrent use of alcohol or other central nervous system (CNS) depressants should be avoided. Combining this medication with alcohol may lead to additional reductions in alertness and further impair CNS performance.

Q: What are the most common side effects of this medication?

A: According to official safety information, the most common side effects reported in clinical studies include somnolence (sleepiness), nasopharyngitis (symptoms of a cold), fatigue, dry mouth, and pharyngitis (sore throat).

Q: What is the correct dose for children under 6 years old?

A: Official product information for the tablet form indicates this product is not approved for use in children under 6 years of age. Other formulations should only be used according to the age and dose instructions printed on that specific product's labeling.

Q: What are the ingredients in the tablet?

A: The active ingredient in Skican tablets is levocetirizine dihydrochloride. The inactive ingredients, which help form the tablet and coating, commonly include substances like lactose monohydrate, microcrystalline cellulose, magnesium stearate, and components of the film coating.

Q: How should I store this medication?

A: Regulatory guidance suggests storing this medication at controlled room temperature, which is typically between 20 C and 25 C (68 F and 77 F). The product should be protected from excessive moisture and heat.

Q: Is it safe to take this while pregnant or breastfeeding?

A: For individuals who are pregnant, official product information recommends seeking advice from a health professional prior to use. Furthermore, regulatory warnings indicate that use during breastfeeding is generally not recommended because the active substance can be excreted in human milk.

Q: Can I take this if I have kidney disease?

A: Official labeling cautions that this product is not appropriate for individuals with severe kidney impairment. Specifically, the product is contraindicated (should not be used) in patients with end-stage renal disease, those on hemodialysis, and children under 12 with impaired kidney function.

Storage Requirements

Skican (Fluconazole) must be stored strictly according to its formulation to ensure stability. All forms must be stored out of the sight and reach of children.

Formulation	Required Conditions	Stability Constraint
Tablets/Capsules	Store at controlled room temperature, typically 20 C to 25 C, in the original, tightly closed container and away from moisture.	No specific in-use constraint.
Oral Suspension (Reconstituted)	Store between 5 C and 30 C. Must be protected from freezing.	Discard any unused portion after 14 days of reconstitution.
Injection Solution	Store at 20 C to 25 C. Must be protected from freezing.	Discard any unused portion after the single-dose use.

Disposal

Expired or unused Skican must not be disposed of via wastewater or household garbage. Follow official regulatory guidance, which mandates returning unwanted medicine to a pharmacist or utilizing a drug take-back program for safe disposal.